Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medinox and Logical Therapeutics have reported positive results for Naproxen Prodrug. LT-NS001, a novel, patented NCE prodrug of the non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed to reduce the GI safety risks, including the formation of ulcers, associated with naproxen.
Subscribe to our email newsletter
The trial was a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs. naproxen in patients aged 45 to 70 years.
In the trial, the patients underwent upper endoscopies at baseline and on day seven. The data shows patients receiving LT-NS001 experienced statistically fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.
There were no serious adverse events and LT-NS001 was well tolerated, said the company.